EMERGING MARKETS
The new year brings new cannabis opportunities
Opportunities in the U.S. cannabis industry continue to expand, despite some setbacks in the November 2022 elections and continuing resistance at the federal level to cannabis reform, writes MJ Biz Daily.
Adding to the recent opening of the New York and Rhode Island markets, a potential four new markets may be opening up this year, including Alabama, Connecticut, Mississippi and Missouri.
The publication shares firsthand insights into potential business opportunities and obstacles in new and emerging state-legal cannabis markets.
LONG GAME
How can the cannabis industry move forward?
We must keep the long game in mind when we think about ending the 85-year policy of marijuana prohibition and criminalisation, writes Justin Strekal of BOWL PAC for Marijuana Moment.
Exploring cannabis policy reform in America, Strekal shares his perspective on how the cannabis industry can effectively navigate the path forward.
“…this is not about betting markets or stock prices, this is about policy reform and removing needlessly oppressive policies that have been in place for nearly a century and harmed millions of families, disproportionately those from historically segregated communities and those without generational wealth,” writes Strekal.
“This will take a tremendous effort and the creation of a movement-moment that harnesses the strengths of our political and cultural realities.”
SCATTERED REGULATIONS
Europe’s maze of regulatory requirements for cannabis medicinal products
In the absence of existing national or European requirements, the regionally competent authorities in our federally organized drug surveillance system define somewhat arbitrarily which requirements for medicinal cannabis are to be valid in their respective jurisdiction, writes Prof. Dr. Markus Veit, Managing Director of Alphatopics GmbH for BusinessCann.
Veit explains that the resulting requirements are not consistent.
In this opinion editorial, Veit explores regulatory requirements in Europe for medical cannabis and what risks this carries for patients.
Veit writes: “The lower end of the scale regarding regulatory requirements is formed by practices by which, for financial reasons, these requirements are tried to be circumvented with the acceptance of the authorities.
“In my opinion these practices are, however, not only inappropriate, but illegal and pose a risk for patients.”
